Introduction
Alzheimer's disease (AD) is the most common form of neurodegeneration and is exemplified by debilitating dementia. It is proposed that ␤-amyloid (A␤) peptides, the proteolytic products of amyloid precursor protein, are toxic and causative in AD, contributing to memory loss and neurodegeneration (Selkoe, 2002) . The A␤1-42 peptide is believed to be the most toxic species, present in various conformational forms (Bitan et al., 2003; Cleary et al., 2005; Shankar et al., 2007) . Evidence suggests that some degree of A␤1-42 oligomerization is necessary for neurotoxicity (Walsh et al., 2002; Kayed et al., 2003; Jan et al., 2011) . Furthermore, multiple soluble assembly forms of A␤1-42 are thought to be both required and sufficient to disrupt neuronal function and subsequent learning and memory Townsend et al., 2006; Poling et al., 2008) .
Structural alterations and oligomerization of A␤1-42 result in a multifaceted dynamic equilibrium of small protofibrillar intermediates in which early oligomeric species act as seeds for fibrillar plaques (Bitan et al., 2003) and thus are of great interest as the primary targets of anti-A␤ therapeutics. A passive anti-A␤ immunotherapy will likely be most beneficial by targeting multiple A␤1-42 assemblies, including soluble oligomers , and other A␤ peptide aggregates that contribute to early events in the A␤1-42 oligomerization process (Frenkel et al., 1998; Lambert et al., 1998; Lee et al., 2006; Spires-Jones et al., 2009 ).
An active immunization approach using an A␤1-42 vaccine was cut short due to safety concerns (Orgogozo et al., 2003) , yet some modest long-term functional benefits were reported in antibody responders (Vellas et al., 2009 ). Active immunization with A␤ carries the risk of adverse immunological responses, leading to inflammation such as meningoencephalitis (Orgogozo et al., 2003) , and also lacks the ability to regulate response level and duration. To mitigate these risks, drug development has focused on passive immunization with antibodies targeting A␤. Although safer, passive immunization may induce antibody-antigen complexes that fully engage Fc␥ receptors (Fc␥Rs) on microglia that may provoke adverse proinflammatory reactions, possibly leading to blood-brain barrier (BBB) disruption observed as vasogenic edema and/or cerebral microhemorrhage (Salloway et al., 2009) .
Here, we describe a humanized anti-A␤ monoclonal antibody [MABT5102A (MABT) ] that targets different A␤ assembly states and contains a human IgG4 backbone with reduced effector function (van der Zee et al., 1986; Tao et al., 1991) . MABT effectively reduces A␤1-42-induced neuronal death and notably promotes microglial A␤ engulfment, but has a significantly reduced capacity to activate microglial Fc␥Rs when compared with an IgG1 subclass.
To directly assess the potential improvement in safety profile, MABT was tested in a single dose, dose-escalation stage, followed by a randomized placebo-controlled, double-blind, parallel multidose (MD) stage phase I clinical study. Patients were also randomized in the MD stage by ApoE status, as previous studies showed that ApoE4 carriers are at higher risk of developing vasogenic edema (Sperling et al., 2012) . Consistent with our hypothesis, MABT showed no signs of vasogenic edema at doses as high as 10 mg/kg single dose, or 5 mg/kg MD over four doses. Pharmacokinetic and pharmacodynamic analysis demonstrated a dose-proportional increase in exposure to MABT and a robust elevation in plasma total A␤ levels, which correlated well with serum MABT concentrations, thus confirming that MABT engaged A␤ in humans.
Materials and Methods
Cell culture preparation. Rat primary cortical cultures were prepared from Sprague Dawley rats (Charles River Laboratories) of either sex at postnatal day 1, as described by Meberg and Miller (2003) . Cerebellum and meninges were removed, and cortices were cut into small pieces and dissociated with enzymatic disruption at 37°C in dissociation buffer (papain, CaCl 2 , EDTA, and HEPES; all from Invitrogen). DNase (Invitrogen) was added for 10 min. Following dissociation, dispersed cortical neurons were plated onto poly-L-lysine (0.01%; molecular weight, 150,000 -300,000; Sigma-Aldrich)-coated 6-well, 24-well, or 96-well tissue culture plates. For immunocytochemistry, cells were grown on coated glass coverslips, into 24-well plates. Cells were maintained in Neurobasal media (Invitrogen) without phenol red, with the addition of L-glutamine (2 mM; Sigma-Aldrich), B27 supplement (Invitrogen), and penicillin/streptomycin (Sigma-Aldrich) in a humidified incubator at 37°C and 5% CO 2 . Following 1 h and 30 min in culture, the medium was replaced with astrocyte-conditioned medium. After further 4 d in culture, cell proliferation was blocked by treatment with cytosine arabinoside at 2.5 M (Invitrogen). Under these culture conditions, 20% of cells were identified as neurons by NeuN/DAPI staining (data not shown). Experiments using mixed cortical cells were generally performed after culturing cells for 6 d in vitro, unless stated otherwise. Enriched microglia prepared from cortex and hippocampus were harvested as described for cortical cultures above. Cortex and hippocampus were put in DMEM containing high glucose and homogenized by pipetting with a 10 ml pipette and then with a syringe. The homogenate was centrifuged for 3 min at 1000 ϫ g, and then resuspended in prewarmed DMEM containing high glucose containing 10% FCS and penicillin/streptomycin (microglia media). The cell suspension was next transferred to a T75 tissueculture flask and kept in a humidified incubator at 37°C and 5% CO 2 for 1 week. The flask was shaken to separate microglia from adherent cells, and collected and washed in DMEM. The resulting cells were resuspended in 1 ml of microglia medium, counted, and plated at 5 ϫ 10 4 cells/well. To verify microglial enrichment, cells were stained with the astroglial and microglial markers GFAP and Iba1, respectively. Greater than 60% of cells stained positive for Iba1, with no cells staining for both GFAP and Iba1. Pure microglia were prepared from postnatal day 3 CX3CR1-GFP mice (The Jackson Laboratory). Cortex and hippocampus was dissected and triturated in DMEM containing high glucose using a 10 ml pipette, and then with an 18 gauge needle. The homogenate was centrifuged for 3 min at 1000 ϫ g, and then resuspended in prewarmed DMEM containing high glucose, 10% FBS, and penicillin/streptomycin (microglia media). The cell suspension was next transferred to a T75 tissue culture flask and kept in a humidified incubator at 37°C and 5% CO 2 for 7-10 d. Microglia were isolated by shaking, collected, and washed in DMEM. The resulting cells were resuspended in 1 ml of microglia medium, counted, and plated on tissue culture-treated glass chamber slides at 5 ϫ 10 4 cells/well for use in experiments. Generation of anti-A␤ antibodies and in vivo efficacy studies. The disulfide-stabilized IgG4 anti-A␤ monoclonal antibody (mAb) MABT is a humanized form of a mouse IgG2b mAb (mMABT) generated by immunizing mice with a vaccine prepared as previously described (Muhs et al., 2007) . For in vivo efficacy, both single-transgenic hAPP (V717I) and double-transgenic hAPP (V717I) /PS1 female 8-to 9-month-old mice were administered 10 mg/kg purified mMABT once weekly, 2 or 14 times, respectively. Brain A␤ plaque load was evaluated by thioflavin-S staining in the hAPP (V717I) mice, and memory performance by novel object recognition test using the hAPP (V717I) /PS1 mice. A␤1-42 aggregation assay. A␤1-42 peptide (Bachem) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol, sonicated, and shaken overnight at room temperature. Aliquots were then dried under a flow of argon, vacuum dried, and stored at Ϫ80°C as monomeric A␤1-42 peptide film. For inhibition of aggregation, antibodies were prediluted in PBS and then added to nonsiliconized incubation tubes containing the following: 10 M thioflavin-T (ThT) (Sigma-Aldrich), 33 M A␤1-42 peptide film, and 8.2% DMSO, with a final 10:1 molar ratio of A␤1-42 to antibody. Incubation was done for 24 h at 37°C, and the spectrofluorescence (excitation, 440 nm; emission, 485 nm) read in six replicates in a black 384-well plate (PerkinElmer) in a microplate reader (Tecan). For disaggregation of preaggregated A␤1-42, the A␤1-42 film was made up as a 110 M solution in 27% DMSO and PBS. This solution was then allowed to aggregate at 37°C for 24 h, after which the following were added: prediluted antibody with a final 10:1 molar ratio of A␤1-42 to antibody and 10 M ThT. This solution was then incubated for additional 24 h at 37°C, after which spectrofluorescence was measured as described above. Inhibition of aggregation and disaggregation is expressed as mean percentage (ϮSEM) inhibition or disaggregation, respectively.
Fc␥R binding. The binding of test antibodies to a panel of human Fc␥Rs was measured using ELISA. Human Fc␥Rs (Genentech) are fusion proteins containing the extracellular domain of the receptor ␥-chain with a Gly/6xHis/glutathione S-transferase (GST) polypeptide tag at the C terminus. A mAb with a human IgG1 framework was used as the positive control (IgG1 control) in this experiment. Plates were coated with a mouse monoclonal anti-GST antibody (Genentech) in a 0.05 M sodium carbonate buffer, pH 9.6, overnight at 4°C. After blocking with an assay buffer containing PBS, 0.5% BSA, and 0.05% Tween 20, the plates were incubated with Fc␥Rs at room temperature for 1 h. Human Fc␥Rs were immobilized to the plate via interaction with the anti-GST coating. Serial dilutions of anti-A␤ MABT, MABT-IgG1, MABT-IgG1-D265A, or IgG1 control mAbs were prepared in the assay buffer containing 10% Blocker Casein in PBS (Pierce). Diluted samples were applied as monomeric forms for the high-affinity receptor (Fc␥RIa), or multimeric forms for the low-affinity receptors (Fc␥RIIa, Fc␥RIIb, and Fc␥RIIIa) . The multimeric forms of test antibodies were generated by cross-linking F(abЈ) 2 fragment of goat anti-human -chain (MP Biomedicals), with test mAb at an approximate molar ratio of 3:1. The plates were incubated with Fc␥Rs at room temperature for 2 h. Plates were washed three times with wash buffer containing PBS and 0.05% Tween 20 after each incubation step. The antibodies bound to the Fc␥Rs were detected with horseradish peroxidase-conjugated F(abЈ) 2 fragment of goat anti-human F(abЈ) 2 (Jackson ImmunoResearch Laboratories). Tetramethylbenzidine (Kirkegaard & Perry Laboratories) served as a substrate. Plates were incubated at room temperature for 15-20 min to allow color development. The reaction was terminated with 1 M H 3 PO 4 , and absorbance at 450 nm with reference at 650 nm was measured on a plate reader (Mo-lecular Devices). Binding curves were generated by plotting the mean absorbance values from duplicates of sample dilutions against the respective sample absorbance.
Preparation of toxic A␤1-42 oligomers. A␤1-42 peptide (Bachem) film was prepared as described above. A 165 g aliquot of peptide film was resuspended in 7 l of DMSO, 85 l of PBS, and 9 l of 2% SDS and incubated for 6 h at 37°C. Then, 300 l of water was added, and after an overnight incubation at 37°C, A␤1-42 oligomers were precipitated with 900 l of 33% methanol 4% acetic acid solution for 1 h at 4°C, centrifuged at 16,200 ϫ g for 10 min. Supernatant was removed and A␤1-42 oligomers were dried before being resuspended in Na 2 HPO 4 /NaCl solution for a final concentration of 1 g/l.
A␤1-42 cellular toxicity assays. The cytotoxicity of A␤1-42 oligomers was tested on mixed cortical cultures at day in vitro 5 (DIV 5). All antibodies, at a final concentration of 100 g/ml, were coincubated with A␤1-42 oligomers for 30 min in serum-free cell culture medium at 37°C before treatment of cells. For some experiments, mixed cortical cultures were pretreated for 1 h with 1 M trans-4- [4-(4- 
, a p38MAPK inhibitor, before treatment with A␤1-42 oligomers. Cell viability was performed by standardized 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assays (Promega), following the manufacturer's instructions. Briefly, for the last 3 h of treatment, cells grown in 96-well plates (Costar) were incubated with the MTT dye solution and the generation of a blue formazan product was measured by reading absorbance at 570 and 690 nm using a microplate reader (Tecan). Results are presented as a percentage increase in survival over A␤1-42 oligomer-treated cells. The ability of the MABT mAb to protect neurons from A␤1-42 oligomer-induced degeneration was also assessed in an in vitro assay using immunofluorescence. Embryonic day 17.5 mouse cortical neurons were isolated, dissociated, and cultured in vitro in Neurobasal media with B27 supplement. A␤1-42 was prepared as described above for A␤1-42 monomeric peptide film, after which 10 l of DMSO was added to dissolve the peptide. Then, 78.6 l of Ham's F12 media was added and the A␤1-42 peptide solution at 25 M was incubated at 4°C for 48 h before cell treatment. Cells were grown for 9 d in total, and were fed on day 3 and on the day of treatment. For treatment, A␤1-42 at 2 M with or without MABT at 50 g/ml was added at day 5 or day 6, with DMSO-F12 alone at the same volume used for the vehicle control. On day 9, following 3 or 4 d of treatment, neurons were fixed and stained with anti-TuJ1 antibody at 1:1000 dilution. FITC-or Alexa Fluor 488-labeled secondary antibodies were used to visualize TuJ1 ϩ microtubules using fluorescence microscopy.
Immunohistochemistry. Paraffin-mounted temporal lobe brain sections (20 m) from an AD patient and from an age-matched non-AD control (Tissue Solutions) were used for immunohistochemistry staining. Deparaffinized sections were subjected to antigen retrieval using formic acid and then labeled with 50 g/ml MABT as the primary antibody. A goat anti-human biotinylated IgG was used as a secondary antibody. Staining was done with diaminobenzidine (Dako) and mounting using Eukitt mounting medium. Images were acquired on a LSM 700 inverted microscope from Zeiss (Carl Zeiss).
Immunocytochemistry and confocal imaging. Cells were grown on glass coverslips. Following treatment, cells were quickly washed with PBS and then fixed with 4% paraformaldehyde for 20 min. After thorough washes, cells were immersed in 100% methanol for 10 min at Ϫ20°C. They were then washed again and incubated in a blocking solution, PBS containing 10% normal goat serum for 1 h at room temperature. After an overnight incubation with the primary antibody, cells were washed and incubated for 2 h with the secondary antibody, and then washed and mounted on glass slides using ProLong Gold antifade reagent (Invitrogen). Epifluorescence and confocal images were acquired on a LSM 700 inverted microscope from Zeiss AG, using a 63ϫ lens. Fluorescence intensity was measured in cell bodies delineated by saturated epifluorescence pictures. Z-stacks were rendered into a three-dimensional image using ImageJ 1.42 (National Institutes of Health; freeware) from which an apical-todistal slice containing the labeled proteins was obtained. Cells treated with HyLite Fluor 488-tagged A␤1-42 were treated in the same way except no primary or secondary antibodies were used to label for A␤1-42. Pure microglial cultures from CX3CR1-GFP P3 pups were treated with 1 g/ml lipopolysaccharide (Sigma-Aldrich), 10 M A␤1-42 oligomers alone or in combination with 100 g/ml anti-A␤ MABT, MABT-IgG1, MABT-IgG1-D265A, control IgG1, or antibodies alone for 30 min. Cells were fixed with 4% paraformaldehyde, washed, permeated with cold methanol, blocked with 10% goat serum in PBS, and stained with rabbit antiphospho-p38MAPK antibody (Cell Signaling Technology).
In vivo imaging of amyloid plaques. Cranial windows were implanted above the somatosensory cortex of 10-month-old transgenic hAPP (V717I) / PS1 female mice, as previously described (Trachtenberg et al., 2002; Holtmaat et al., 2009) , 2 weeks before the initial imaging session. Twenty-four hours before each imaging session, animals were peripherally injected with 10 mg/kg methoxy-X04 intraperitoneally to visualize individual amyloid plaques (Klunk et al., 2002) and immediately before imaging injected intravenously with AngioSense680 (VisEn Medical) to visualize blood vessels. For each imaging session, animals were anesthetized with an isoflurane-oxygen mixture and mounted to the microscope using a head post. Images were collected via a two-photon laser-scanning microscope (Ultima In Vivo Multiphoton Microscopy System; Prairie Technologies) using a Ti:sapphire laser (MaiTai DeepSee Spectra Physics; Newport) tuned to 820 nm delivering ϳ30 mW to the back-focal plane of a 40ϫ, NA 0.8 objective lens (Olympus Imaging). The pattern of the vasculature was used to reproducibly position the mouse relative to the objective from day-to-day enabling individual amyloid plaques to be imaged over many weeks. The volumes of individual plaques were estimated by summing the number of pixels above background within a region of interest drawn around a given plaque. Background is defined as the mean pixel intensity plus 2 SDs within a region of interest drawn adjacent to an amyloid plaque. Following the fourth and eighth imaging session, animals were dosed intraperitoneally with 60 mg/kg MABT.
Phospho-p38MAPK ELISA. Rat cortical cultures were seeded onto poly-L-lysine-coated six-well cell culture plates (Costar) and used at DIV 5. Unless otherwise indicated, cells were treated with 2 M A␤1-42 oligomers with or without mAb at 100 g/ml for 30 min. In some assays, cells were pretreated for 1 h with the p38MAPK inhibitor SB239063. Anisomycin was used as a positive control. Treatments were stopped by placing cells on ice and aspirating the medium. Cells were washed with ice-cold PBS, harvested using a cell scraper, and lysed in buffer consisting of 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 mM sodium orthovanadate, 1% Triton X-100, and containing protease and phosphatase inhibitor cocktails. Protein concentration was determined by the BCA assay (Pierce). For semiquantitative measure of p38MAPK activation, a rat phospho-p38MAPK colorimetric ELISA kit was used (Cell Signaling Technology), following manufacturer's instructions. Plates were read on a spectrophotometric microplate reader (Tecan) at a 370 nm.
TNF␣ release. Rat cortical cultures enriched for microglia (Ͼ60% Iba1 ϩ of total DAPI ϩ cells) were treated with 10 M A␤1-42 oligomers with or without 100 g/ml antibodies for 6 or 24 h. Lipopolysaccharide (Sigma-Aldrich) at 1 g/ml was used as a positive control stimulus. Cell supernatants were removed at the indicated time points, passed through a 0.2 m filter, and tested for TNF␣ with a Quantikine rat TNF␣/ TNFSF1A (R&D Systems), following the manufacturer's instructions.
Statistical analysis. All statistical analyses were done using GraphPad Prism, version 5 (GraphPad Software). Data are presented as means Ϯ SD or SEM, as indicated. Data were analyzed by Student's t test, one-way ANOVA followed by Tukey's post hoc multiple comparisons, or Wilcoxon's rank sum nonparametric test when appropriate. A value of p Ͻ 0.05 was taken to indicate a statistically significant difference.
Results

Generation of a humanized IgG4 antibody, MABT, that binds multiple A␤ conformations
Murine anti-A␤ monoclonal antibodies were generated by immunizing mice with an A␤ peptide antigen using a liposomal vaccine formulation as previously described (Muhs et al., 2007; Hickman et al., 2011) . Several criteria were used to select candidate antibodies, including the ability to bind multiple A␤ species and to inhibit A␤1-42 assembly into small cytotoxic peptide aggregates. A monoclonal murine mAb with an IgG2b backbone (mMABT) was selected for in vivo efficacy studies using both singletransgenic hAPP (V717I) and doubletransgenic hAPP (V717I) /PS1 female mice. When compared with vehicle control, treatment with mMABT reduced plaque load in mMABT-treated mice by 31%, and improved memory performance with a 32% increase in recognition index as observed in a novel object recognition test (Fig. 1 A) . The mMABT was further affinity matured and humanized onto an IgG4 backbone (referred to as MABT). To test the binding of MABT to A␤ in vitro, we made a series of different A␤1-42 preparations. The binding of MABT was measured by ELISA, and similar to the mMABT ( Fig. 1 B) , was shown to be highly comparable among the different A␤ peptides (Fig. 1C) or A␤1-42 assembly states (Fig. 1 D) .
MABT was subsequently tested for binding to A␤ plaques in the brains of transgenic mice expressing the human amyloid precursor protein (hAPP (V717I) ) and to amyloid plaques in human AD brain sections. Amyloid plaques in both hAPP (V717I) transgenic mice ( Fig. 1 E, top) and in AD brain ( Fig. 1 E, bottom) were immunodecorated with the MABT mAb. Together, these data provide evidence of MABT binding to both soluble A␤ oligomers and A␤ aggregates present in AD brains.
Inhibition of A␤ assembly and disaggregation of preformed protofibrillar A␤ peptides by MABT
The binding epitope of MABT was mapped to amino acids 12-23 of A␤1-42, and therefore overlaps with the main hydrophobic cationic segment of A␤1-42 responsible for the self-association, subsequent oligomerization, and the core of A␤1-42 ␤-sheet assembly (Pike et al., 1993; Esler et al., 1996; Haass and Selkoe, 2007) . We therefore hypothesized that MABT would inhibit A␤1-42 assembly and possibly dissociate preaggregated A␤1-42. This prompted us to evaluate the effects of MABT on in vitro A␤1-42 aggregation using ThT, a dye that does not impede with amyloid assembly but fluoresces upon binding to amyloid aggregates rich in ␤-sheets (LeVine, 1993). When we compared MABT to a control anti-A␤ mAb directed against the N terminus of A␤1-42, and thus not overlapping with the core amino acids that form the self-assembly domain, MABT demonstrated 83% greater inhibitory effect on A␤1-42 aggregation in a ThT assay (Fig. 1 F, left  panel) . Similarly, an 80% greater dissociation of preaggregated A␤1-42 peptide was observed, when compared with the control N terminus anti-A␤ mAb ( Fig. 1 F, right panel) . These in vitro assays are based on the ability of ThT to bind to extended ␤-sheets of the A␤1-42 peptide (LeVine, 1993) . Therefore, to verify that this was not an artifact due to potential mAb-mediated displacement of ThT binding to ␤-sheet rich A␤1-42, we performed an assay that does not rely on ThT fluorescence, but rather on the capacity of labeled A␤1-42 to aggregate or self-assemble onto immobilized unlabeled A␤1-42. We obtained comparable results in this assay, namely that MABT prevented the self-assembly (Ϯ95% CI) . B, C,AnA␤ ELISA was used to compare the binding to human and murine A␤1-42 and human A␤1-40, for mMABT (B) and MABT (C). D, MABT was also tested for binding to different A␤1-42 assembly states, showing equal binding for oligomers, monomers, and fibers. E, MABT binds A␤ plaques present in brain sections from transgenic hAPP (V717I) mice (top panels) and human AD temporal neocortical sections (bottom panels). F, In vitro functionality was shown by the ability of MABT to impede A␤1-42 aggregation (left panel), and to disassemble preformed A␤1-42 aggregates (right panel) in a ThT-based assay, with an A␤1-42 to MABT molar ratio of 10:1. An anti-A␤ IgG mAb with a N-terminal epitope was used as control. Results show the mean (ϮSD) of three independent experiments. *p Ͻ 0.05; **p Ͻ 0.01. G, MABT was also tested in an A␤1-42 self-assembly assay that does not rely on ThT fluorescence upon binding to multimeric A␤ assemblies, as described in Materials and Methods. The means (ϮSEM) of two assays are shown.
of A␤1-42 in a dose-dependent manner (Fig. 1G ). These data suggest that an antibody directed against the mid-domain of A␤, yet maintaining binding to aggregated A␤, may provide the most robust inhibitory effect on A␤1-42 fibril elongation and/or aggregation relative to antibodies targeting other domains of A␤.
MABT neutralizes the neurotoxic effects of A␤ oligomers in vitro
We next investigated the effects of MABT in a primary cell culture model using cytotoxic A␤1-42 oligomers. Primary cortical cultures from P1 rats were grown and treated with free A␤1-42 oligomers or oligomers bound to MABT. Treatment of cortical cultures with 2.5 or 5 M A␤1-42 oligomers over 24 h resulted in a reduction in metabolic activity as measured by mitochondrial oxidation of MTT (Fig. 2 A) , an indicator of cell viability. A complete rescue from toxicity was observed for A␤1-42 oligomer concentration up to 5 M in the presence of MABT (MABT to A␤1-42 molar ratio of 1:7.5) compared with control IgG. To confirm these results, ATP release was measured using a luminescence assay, showing a similar neuroprotective effect of MABT (Fig. 2 B) . To further assess the effect of MABT on A␤1-42-mediated neurodegeneration, mouse embryonic cortical neurons were cultured for 6 d, and treated with A␤1-42 with or without MABT for 4 d. Control cultures showed healthy morphology (Fig. 2C, left  panel) . Treatment with A␤1-42 for 4 d resulted in robust neurite degeneration (Fig. 2C, center panel) . Cells treated with the combination of A␤1-42 and MABT appeared similar to control cells (Fig. 2C , right panel). For these assays, a mixture of cytotoxic A␤1-42 oligomer assemblies was used, ranging in size from dimers and trimers to higher-molecular-weight multimers (Fig. 2 D) . These results show that MABT was able to protect primary neurons from A␤1-42 oligomer-induced degeneration.
A␤1-42 oligomer interaction with neurons is inhibited by MABT
A␤ peptides, especially aggregation intermediates (Bateman et al., 2007) , are known to associate with various lipids and proteins present in cell membranes. We hypothesized that MABT may exert its neuroprotective effects by reducing binding of A␤1-42 oligomers to neurons. To test this idea, an immunofluorescent staining for membrane-bound A␤ was performed. A␤1-42 oligomers were applied to mixed cortical cultures for 30 min or 18 h, after which cultures were stained for A␤ and the neuron-specific class III ␤-tubulin, TuJ1. We observed that treatment of cortical neurons with A␤1-42 oligomers resulted in A␤ binding to neurons, particularly localized to neuritic processes (Fig. 3A , middle panels and insets). Cotreatment with MABT blocked the interaction of A␤1-42 oligomers with neurons. This effect was readily apparent as early as 30 min (Fig.  3 A, B) and remained for at least 18 h of treatment (Fig. 3B) . Although we used an N-terminal anti-A␤ mAb (clone 6E10) to stain for A␤1-42 oligomers in our assay (Fig. 3A) , thus reducing the potential for interference between MABT and the detection mAb used for staining, we confirmed these results using HiLyte Fluor-488 fluorescently labeled A␤1-42. Treating cortical cultures with this directly labeled A␤1-42 peptide further supported the conclusion that MABT reduced binding of A␤1-42 to neuronal processes in primary cortical cultures (Fig. 3C,D) .
Observations from immunofluorescent studies also indicated that, in the presence of MABT, there was a shift in A␤1-42 oligomer association away from neuronal processes toward cellular profiles that resembled microglia (Fig. 3E ). This may be expected for an antigen-antibody complex binding to microglia through an Fc␥R-mediated mechanism (Clark, 1997), but was unexpected for the effector-reduced MABT, which required further investigation. An MTT assay was used to determine cell viability as described in Materials and Methods. The means (ϮSEM) of five independent experiments are shown. *p Ͻ 0.05; **p Ͻ 0.01. B, In a comparable assay, but measuring ATP production as a marker of metabolic activity, cells were treated with 10 M A␤1-42 oligomers with or without 200 g/ml MABT. Results show the means (ϮSEM) of two independent assays. C, Neurotoxicity following extended A␤1-42 oligomer treatment was tested by morphological analyses. Cells as above were treated for 4 d with 10 M A␤1-42 oligomers, with or without 50 g/ml of MABT, and then stained for TuJ1 (green) and DAPI (blue). D, Silver-stained SDS-PAGE showing the highly cytotoxic A␤ oligomer preparations consisting of a mixture of A␤1-42 oligomer assemblies, ranging in size from dimers and trimers to higher-molecular-weight multimers.
A role for effector function in microglial uptake of A␤ oligomers We next explored the relationship between MABT/A␤1-42 complex formation and microglial uptake of A␤1-42. To verify that A␤1-42 oligomers bound to MABT are indeed taken up by microglia, confocal imaging on treated mixed neuronal cultures was performed. When compared with cells treated with A␤1-42 oligomers alone, we found that MABT mediated rapid uptake of A␤1-42 oligomers into cellular profiles likely to be microglia (Fig. 4 A) . This was readily apparent as early as 30 min following treatment. Microglia play a crucial role in uptake and degradation of A␤, a function that is postulated to be compromised in APP transgenic mice (Hickman et al., 2008) . Relative to anti-A␤ immunotherapy, it has been proposed that one possible mechanism whereby A␤ plaques are cleared is through the Fc␥R binding properties of anti-A␤ bound to A␤ (KoenigsknechtTalboo et al., 2008) . However, uptake of anti-A␤/A␤ complexes by microglia and Fc␥R activation may trigger these cells to become activated.
In addition to overcoming the direct cytotoxicity of A␤1-42 oligomers on neurons, a therapeutic anti-A␤ antibody ideally would have a reduced proinflammatory response. We therefore compared MABT to antibodies carrying the same antigen binding sequences, but harboring different IgG backbones with variable Fc␥R binding affinities, and therefore different microglia activating potential. These included a wild-type human IgG1 with full Fc␥R binding capacity (MABT-IgG1), and a human IgG1 backbone carrying a D265A mutation (MABT-IgG1-D265A) that dramatically reduces Fc␥R binding (Shields et al., 2001 ). All of the backbone variants tested bound with similar affinity to A␤1-42, as verified using surface plasmon resonance (data not shown). The ability of these different mAb backbones to internalize A␤1-42 oligomers into microglia was then compared using confocal imaging on A␤1-42 oligomertreated primary cortical microglia. We found that A␤1-42 oligomer internalization correlated well with Fc␥R binding, with MABT-IgG1 Ͼ MABT Ͼ MABT-IgG1-D265A (Fig. 4 B, C) . To verify that microglia are indeed the cells taking up A␤1-42 complexed to mAbs, we repeated the study using HiLyte Fluor 488-tagged A␤1-42 and costained for the microglial marker Iba1. Upon binding to either MABT or MABT-IgG1, tagged A␤1-42 became enriched in Iba1 ϩ microglia (Fig. 4 D) . We also observed that, in cell cultures treated with A␤1-42 in combination with MABT-IgG1, microglia had more condensed nuclei and brighter Iba1 staining, features suggesting greater antigen/antibodymediated microglial activation.
To verify the differences in Fc␥R binding between MABT backbone variants, we measured the binding of the different cross-linked IgG mAb to Fc␥RIIIa-V158 and, as expected, found a hierarchy of binding such that MABT-IgG1 Ͼ MABT Ͼ MABT-IgG1-D265A (Fig. 4 E) . Comparable results were obtained with other members of the Fc␥R family (data not shown).
We next compared the different MABT variants for their ability to reverse A␤1-42 oligomer-mediated toxicity in mixed primary cortical cultures. Functional Fc␥R binding activity, present for both the MABT and MABT-IgG1 mAbs, was required for full reversal of A␤1-42 oligomer-mediated toxicity (Fig. 4 F) . The MABT-IgG1-D265A mAb, which lacks Fc␥R binding functionality, showed only a nonsignificant trend toward reversal of A␤1-42 oligomer-mediated cellular toxicity. Perhaps surprisingly, the MABT-IgG1 wild-type mAb, which bears greater Fc␥R binding affinity compared with the IgG4 MABT, trended toward a smaller protective effect when compared with MABT. We hypothesized that, while binding to microglial Fc␥Rs is needed for full rescue, the enhanced binding of the MABT-IgG1 backbone to Fc␥Rs compared with that of a MABT may result in undesired microglia activation, which may translate into reduced overall protection against A␤1-42 oligomer-mediated neurotoxicity. Cortical cultures from P1 rats were treated as described for A, except that A␤1-42 tagged with HyLite Fluor 488 was used. Green is A␤1-42 and blue is DAPI, with one representative experiment shown. D, Green fluorescence was quantified, with the mean (ϮSD) of the two independent experiments shown. E, Upon treatment with MABT, A␤1-42 oligomers appeared to be taken up by cells resembling microglia. Green is A␤1-42 and blue is DAPI.
Therefore, in addition to having the ideal A␤ binding properties, optimizing the level of microglial activation may be crucial in developing an anti-A␤ therapeutic antibody with the desirable safety and efficacy properties.
Having observed that MABT can efficiently promote A␤ engulfment by microglia in vitro, we assessed whether systemic administration of MABT in hAPP (V717I) transgenic mice could induce amyloid plaque removal in vivo. As the antibodies we . A␤1-42 oligomers are taken up via an FcR-mediated mechanism into microglia upon MABT treatment. A, Confocal imaging was used to show that A␤1-42 oligomers complexed to MABT are taken up into microglia. A␤1-42 oligomers are shown in red, and blue is DAPI. An apical-to-distal slice was obtained from a three-dimensional image rendered from Z-stacks. Confocal imaging was done on mixed cortical cells labeled for A␤ (red) and DAPI (blue) as described in Materials and Methods. B, C, Microglia were identified and scanned for the maximum fluorescence intensity through a series of confocal stacks representing intracellular locations (B), and the total area of fluorescent signal above a minimum threshold was quantified (C). Each mark on the graph represents the total area of A␤ staining within a single cell. A minimum of 20 cells was analyzed for each treatment condition. Data were compared using one-way ANOVA followed by Tukey's post hoc multiple comparison. Means (ϮSEM) are shown. D, Microglia (Iba1 ϩ ) was verified as the cell type taking up A␤1-42 complexed to MABT. Red is Iba1, green is HyLite Fluor 488-labeled A␤1-42, and blue is DAPI. E, Differential binding to Fc␥RIIIa-V158 was verified in a binding assay. F, An anti-A␤ mAb requires effector function via Fc␥R binding for full protective effect against A␤1-42 oligomer toxicity. Mixed cortical cells from P1 rats were treated with A␤1-42 oligomers, with or without MABT, MABT-IgG1-D265A, MABT-IgG1, or an IgG1 control mAb. The graph shows the mean (ϮSEM) percentage increase in cell survival compared with A␤1-42 oligomer treated cells, from five independent experiments. Statistical analysis was done using one-way ANOVA followed by Tukey's post hoc multiple comparison. generated used human backbones, we were unable to conduct chronic dosing studies as is commonly done for murine antibodies, both because human antibodies can robustly induce an antitherapeutic antibody response and because there is not a murine version of human IgG4 that replicates the Fc receptor binding profile (Fig. 4 E) . Thus, using in vivo live-imaging preparations in a short course of dosing, we confirmed the ability of MABT to promote glial engulfment of A␤ by analyzing individual plaques in 10-month-old hAPP (V717I) /PS1 transgenic mice over several weeks (Fig. 5A ). On average, individual plaques increased in volume over the initial 3 week imaging period (Fig. 5B , average week-to-week normalized change in volume; 0.156, 0.060, and 0.081). Following a single peripheral MABT administration (60 mg/kg, i.p.), plaque volume decreased over the 3 week period after dosing (average week-to-week normalized change in volume; Ϫ0.036, Ϫ0.034, and Ϫ0.034). A second dose of MABT was administered to a single animal and seven plaques were followed by imaging, three of which were completely removed by week 9. These observations are consistent with our in vitro data suggesting that MABT can induce A␤ removal, presumably via microglia uptake.
Reduced microglia response with MABT
To identify downstream mediators of A␤1-42 oligomer-induced toxicity, we examined a number of candidate signaling pathways. We focused our efforts on examining p38MAPK, which has been shown to contribute to neurotoxicity and microglial activation (Li et al., 2004; Wang et al., 2004) . We first examined p38MAPK activation in primary mixed cortical cultures treated with A␤1-42 oligomers alone, or in combination with the anti-A␤ MABT, MABT-IgG1, MABT-IgG1-D265A, or a control IgG1 that does not bind to A␤. When cells were treated with A␤1-42 oligomers, p38MAPK was activated within 15 min (data not shown) and reached a maximum at 30 min. After combining with the different mAbs, only MABT-IgG1, carrying the IgG1 wildtype backbone and thus having the greatest binding affinity to Fc␥R, significantly increased the A␤1-42 oligomer-induced p38MAPK activity above A␤1-42 baseline levels, as shown by a phospho-p38MAPK-specific ELISA (Fig. 6A) . Since the various anti-A␤ antibodies bind with similar affinity to A␤1-42, the MABT-IgG1 mAb should neutralize toxic A␤1-42 oligomers to the same degree as MABT. However, the greater Fc␥R binding affinity of the IgG1 backbone may result in microglia activation that can be detrimental to cells that are highly susceptible to the actions of A␤1-42 oligomers, such as neurons. MABT complexed to A␤1-42 oligomers did not reduce the A␤1-42 oligomer-induced p38MAPK activity, but rather showed a trend toward higher activity, possibly reflecting the partial Fc␥R activation by this antibody.
As these initial assays measured the total p38MAPK activity in mixed cortical cultures, including both neuronal and glial cells, we wanted to know whether the p38MAPK activity detected when cells were treated with the combination of A␤1-42 oligomers and MABT was specific to microglia. Cells were treated as previously, but this time phospho-p38MAPK activity was examined by immunofluorescence staining along with the microglia marker Iba1. Upon treatment with A␤1-42 oligomers complexed to MABT or MABT-IgG1 mAbs, ϳ93% of cells staining positive for phospho-p38MAPK were Iba1 ϩ (Fig. 6 B) . To confirm the activation of p38MAPK in microglia, we treated purified microglia in the same way. Under these conditions, A␤1-42/IgG complex-mediated p38MAPK activation in microglia was readily identified (Fig. 6C) .
To address the contribution of p38MAPK activation to A␤1-42 oligomer-mediated neurotoxicity, we next treated cells with a second-generation p38MAPK-specific inhibitor, and then with A␤1-42 oligomers alone or in combination with either the MABT or the low-Fc␥R binding MABT-IgG1-D265A mAb. Unexpectedly, the MABT-mediated increase in MTT signal was reduced to that of MABT-IgG1-D265A in presence of the p38MAPK inhibitor, indicating a reduction in MABT-mediated rescue function upon p38MAPK inhibition (Fig. 6 D) . As predicted, p38MAPK inhibition had no effect on cells treated with A␤1-42 oligomers complexed with the MABT-IgG1-D265A mAb. This indicates that, although the MABT mAb does not significantly induce p38MAPK levels over those seen with A␤1-42 oligomers alone, p38MAPK activation does play a role in MABT-mediated neuroprotection. The cellular target of this activity in the mixed culture system is not known.
To link the increased microglia activity more directly to a downstream proinflammatory readout, we measured TNF␣ release by primary cell cultures enriched for microglia (Ͼ61% Iba1 ϩ ; data not shown). The release of proinflammatory TNF␣ by enriched microglia when treated with A␤1-42 oligomers was reduced in the presence of all anti-A␤ mAbs tested (Fig. 6 E) . However, the greatest effect was observed in the presence of MABT. Thus, MABT has a more desirable profile compared with MABT-IgG1, combining both the neuroprotective effects with the ability to promote A␤ engulfment by microglia with limited microglial activation. Similar results were observed when evaluating other canonical cytokines; however, these cytokines were not consistently upregulated by the addition of our A␤ oligom- (V717I) /PS1 animals were labeled with methoxy-X04 injected intraperitoneally, visualized by in vivo two-photon microscopy, and tracked over multiple weeks. B, The relative change in plaque volume over time plotted as fold increase from the initial imaging session. On average, the individual plaque size decreased in volume after systemic dosing with MABT (14 plaques, 2 animals). Figure 6 . MABT reduces microglial activation as measured by p38MAPK activity and TNF␣ secretion. A, When complexed to A␤1-42 oligomers, the IgG1 wild-type backbone significantly increases p38MAPK activation over that shown for A␤1-42 oligomer-treated microglia. Mixed cortical cells from P1 rats were treated with 10 M A␤1-42 oligomers for 30 min with or without 100 g/ml MABT, MABT-IgG1-D265A, or MABT-IgG1 wild type. An IgG1 mAb not binding to A␤ was used as control. The activity of p38MAPK was measured by a phosphospecific ELISA as described in Materials and Methods. The mean (ϮSEM) of four independent experiments is shown. Statistical analysis was done using one-way ANOVA followed by Tukey's post hoc multiple comparison. B, Activation of p38MAPK with A␤1-42 oligomers complexed with mAb is specific to microglia. Cells were treated as described above and then stained for phospho-p38MAPK (green), Iba1 (red), and DAPI (blue). The panels from left to right show the following: treatment with buffer control, A␤1-42 oligomers, and A␤1-42 oligomers with MABT. C, Pure microglia from CX3CR1-GFP mice were used to verify microglia-specific p38MAPK activity. The top panels show phospho-p38MAPK immunofluorescence (red), whereas the bottom panels are a merge of phospho-p38 and GFP (green) on a phase contrast image. D, p38MAPK activity is required for the full protective effect of MABT against A␤1-42 oligomer toxicity. Mixed cortical cells from P1 rats were treated (Figure legend continues.) ers; thus, our efforts were focused on evaluating p38MAPK activation and TNF␣ secretion as consistent measures of microglial activation.
Reduced risk of vasogenic edema with MABT observed in a phase I clinical study A phase I, randomized, placebo-controlled, double-blind, multicenter clinical study was conducted with the primary objective to determine the safety and tolerability of intravenous MABT in patients with mild-to-moderate AD. Secondary objectives of this study were to characterize pharmacokinetics and A␤ pharmacodynamics after single and multiple doses of MABT in AD patients. The study consisted of a single-dose (SD), dose escalation stage, followed by a randomized placebo-controlled, doubleblind, parallel multidose (MD) stage (Fig. 7A) . The main patient selection criteria included diagnosis of AD (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria), mini-mental state examination score of 15-26 (inclusive) at screening, and a 50 -86 years of age range. The actual patient population included in the study are outlined in Figure 7B .
No patients receiving MABT developed vasogenic edema, in either the single or multidose study. Importantly, patients were genotyped and randomized in the multidose study to ensure that at least 40% of enrolled patients were ApoE4 carriers (48% were carriers), as these patients were previously shown to be at higher risk of developing vasogenic edema (Salloway et al., 2009 ). The serum concentration-time profiles for MABT following both a single dose (0.3-10 mg/kg) and four weekly doses (0.5-5 mg/kg) increased in proportion to dose and were characterized by slow clearance (ϳ3 ml ⅐ d Ϫ1 ⅐ kg Ϫ1 ) and a long half-life (18 -23 d) (Fig. 7C) . A dose-dependent elevation in plasma total A␤ levels was observed following single or weekly intravenous administration, which correlated well with serum MABT concentrations (Fig. 7D) , thus suggesting substantial target engagement in vivo. These data suggest that an anti-A␤ antibody targeting a wide array of A␤ assembly states, including aggregated A␤, combined with a human IgG4 backbone with reduced effector function, can be safely dosed in humans at relatively high levels, thus improving CNS exposure. Additional clinical trials are underway to assess the efficacy of MABT (crenezumab).
Discussion
Recent clinical results using both active and passive immunization to target A␤ in AD patients have identified a number of challenges (Orgogozo et al., 2003; Lee et al., 2005; Salloway et al., 2009) ; thus, great emphasis has been placed on developing alternative strategies toward a safer and more effective immunotherapy for AD. A major theme of the safety findings from these trials, particularly with passive immunotherapy, is disruption of the BBB as observed by magnetic resonance imaging showing signs of vasogenic edema and/or microhemorrhages (Salloway et al., 2009) . Mechanisms underlying these dose-limiting observations have been proposed (for review, see Weller et al., 2009) . A prominent immunotherapy-specific hypothesis is that the immune functions of the particular anti-A␤ antibody and/or its binding properties are central to the risk associated with these BBB integrity findings (Wilcock et al., 2004 . It has also been hypothesized that these safety findings are inseparable from the mechanisms driving efficacy of immunotherapy (Weller et al., 2009) ; however, the evidence to support this claim is lacking. For example, previous studies have shown that completely effectorless murine anti-A␤ antibodies are capable of reducing plaque load in mice, while reducing the risks associated with vascular damage (Carty et al., 2006; Wilcock et al., 2006) . Nevertheless, these studies did not directly test the ability of these antibodies to promote microglial engulfment of A␤. Also, these studies were conducted with antibodies that only bind to the less toxic C-terminal region of A␤1-40. Ideally, an anti-A␤ immunotherapy approach would combine the essential A␤ binding properties to maximize efficacy with the appropriate immune modulation to limit safety findings.
We show that anti-A␤ antibody effector function can be modulated to maintain A␤ engulfment properties, while limiting activation of microglia that may ultimately be deleterious to the vascular and nervous systems. Furthermore, targeting a unique epitope on A␤ has allowed us to identify an antibody that binds multiple forms of A␤, including oligomeric forms, while inhibiting aggregation and promoting disaggregation of A␤. Together, the reduced effector function of MABT, a humanized anti-A␤ IgG4 antibody, and its unique A␤ binding profile exclusively position this anti-A␤ immunotherapy candidate to test both mechanisms of efficacy and safety in the clinic. Indeed, phase I data presented in this report are consistent with this hypothesis, showing that, at dose levels and exposure Ͼ10-fold compared with other anti-A␤ mAbs on human IgG1 backbones (Salloway et al., 2009; Ostrowitzki et al., 2012) , MABT showed no signs of vasogenic edema. Interestingly, however, solanezumab is also on a human IgG1 backbone, but has not shown the same level of vasogenic edema as other human IgG1 anti-A␤ antibodies (Carlson et al., 2011) . This is likely because solanezumab does not recognize aggregated A␤ and thus does not bind vascular amyloid and elicit an immune response causing disruption of the blood-brain barrier.
Having identified an anti-A␤ antibody with in vivo efficacy and unique binding properties, we set out to investigate the ability of MABT to inhibit A␤-mediated cellular toxicity. A recent study has demonstrated that the two adjacent histidines at position 13 and 14 of A␤ are necessary for cell membrane binding and uptake (Poduslo et al., 2010) . These histidine residues overlap with the epitope of MABT, thus predicting the results of A␤ cellular binding studies in which we observe robust inhibition of A␤ binding to neurons. In addition to blocking A␤ interaction with neurons, we see that toxicity mediated by A␤ oligomers is also inhibited; thus, MABT is neuroprotective to toxicity mediated by A␤.
In the process of evaluating A␤-mediated cellular toxicity in mixed neuronal culture systems, which include neurons, microglia, and astrocytes, we observed an accumulation of A␤ after treatment with MABT in an unidentified cell type not resembling a neuron. Further investigation identified this cell type as microglial, based on Iba1 staining and confirmed in studies using purified CX3CR1-GFP microglia. We were intrigued by these initial observations, as MABT is an IgG4 antibody, which has reduced Fc␥R binding properties compared with a wild-type IgG1 and 4 (Figure legend continued. ) with 10 M A␤1-42 oligomers alone or together with 100 g/ml MABT or MABT-IgG1-D265A, in the presence or absence of 1 M SB239063, a p38MAPK-specific inhibitor. A cytotoxicity assay using the MTT readout was performed after 24 h. The mean (ϮSEM) of four experiments is shown. Statistical analysis was done using one-way ANOVA followed by Tukey's post hoc multiple comparison. E, IgG1 is less effective in reducing A␤1-42-mediated proinflammatory release by microglia as measured by TNF␣ levels from conditioned media of enriched microglia following 24 h of treatment. The mean (ϮSEM) of three independent experiments is shown. Statistical analysis was done using one-way ANOVA followed by Tukey's post hoc multiple comparison. may therefore be less effective at promoting A␤ engulfment (for review, see Nimmerjahn and Ravetch, 2006) . Thus, to explore the relative contribution of IgG isotype and associated effector function to A␤ engulfment by microglia, we generated two additional variants of MABT with equal binding affinity to A␤, but one with full effector function (MABT-IgG1) and one with no effector function (MABT-IgG1-D265A). Using these reagents, we observed that MABT-IgG4 was nearly as effective as the IgG1 variant at promoting A␤ engulfment. In contrast, MABT-IgG1-D265A showed modest-to-little promotion of A␤ engulfment. These data suggest that effector function may be necessary for A␤ engulfment; however, modest binding to Fc␥Rs may be sufficient to obtain the desired microglial uptake while limiting activation and a proinflammatory response. Furthermore, we confirmed that MABT could reduce A␤ pathology in vivo using live imaging in hAPP (V717I) /PS1 transgenic mice to assess plaque dynamics after dosing.
Unlike Fc␥R binding, neonatal Fc receptor (FcRn) binding is not substantially different between IgG4, IgG1, and IgG1-D265A. Although it is notable that altering Fc␥ receptor binding alone is sufficient to alter ability of microglial engulfment of A␤, this does not rule out the possibility that completely effectorless anti-A␤ antibodies may be efficacious in vivo via a FcRn-mediated mechanism. Indeed, previous studies have shown that effectorless antibodies are efficacious in vivo (Carty et al., 2006; Wilcock et al., 2006) ; furthermore, an FcRn-driven mechanism of anti-A␤ action has been directly investigated, suggesting that A␤/anti-A␤ complexes are cleared across the blood-brain barrier via an . D, Increases in plasma total A␤1-40 and total A␤1-42 correlated well with serum MABT concentration following single or weekly administration in the SD phase; serum MABT and plasma total A␤ samples were collected just before MABT administration through study day 112. In the MD phase, samples were collected just before MABT administration on day 0, at 1 h and 7 d after each dose and to 119 d after last dose through study day 140. Serum MABT concentrations were determined using a quantitative ELISA with a limit of detection (LOD) of 0.0225 g/ml. Total plasma levels of A␤1-40 and A␤1-42 were determined using an electrochemiluminescence assay with a LOD of 0.01 and 0.125 nM, respectively. A␤1-42 was not detectable in patients given placebo (or at baseline in patients given MABT) so is not shown.
FcRn-dependent pathway (Deane et al., 2005) . Thus, in addition to the IgG4-dependent ability of MABT to drive microglial engulfment of A␤, it is also reasonable to propose that MABT could use FcRn to enhance its activity in vivo.
Interestingly, MABT-IgG4 and MABT-IgG1 were both neuroprotective; however, the antibody that had no remaining Fc␥R binding, MABT-IgG1-D265A, was less protective to A␤-mediated cellular toxicity. Even if full effector function via Fc␥R binding plays a role in the ability of MABT to promote microglial engulfment of A␤, MABT-IgG1 did not demonstrate better neuroprotection and may have even shown a trend toward reduced efficacy. We therefore hypothesize that the robust effector function of an anti-A␤ IgG1 antibody, when complexed to A␤, may aberrantly initiate or augment a proinflammatory response that is detrimental for neuronal cell survival.
There is substantial evidence that microglia are robustly activated in many neurodegenerative diseases, including AD, and that activation may be either neuroprotective or neurotoxic depending on yet poorly understood factors (for review, see Ransohoff and Perry, 2009 ). The p38MAPK pathway plays a central role in the signaling network responsible for the upregulation of proinflammatory cytokines in microglia, such as TNF␣, and regulates their biosynthesis by multiple mechanisms (Simon et al., 1985 ; J. C. Lee et al., 1994; Gallagher et al., 1997; Y. B. Lee et al., 2000) . We therefore assayed for p38MAPK response after A␤ treatment and found that MABT-IgG1 with full effector function produced the greatest activation of p38MAPK in microglia. We also tested for differential effects on TNF␣ release, a downstream response to p38MAPK activation; all MABT variants tested reduced the release of TNF␣ by microglia; however, this effect was significantly blunted for MABT-IgG1, which has full effector function. Although there is a well documented role of p38MAPK in stress-induced and proinflammatory signaling, there is also evidence for a supportive function of p38MAPK in A␤ phagocytosis (Doyle et al., 2004) and nonamyloid processing of APP (Bandyopadhyay et al., 2006) . These previous findings may explain why the low p38MAPK activity measured from mixed neuronal cultures treated with A␤ and MABT appears to be required for full rescue from toxicity, as the neuroprotective effect of MABT was significantly reduced in the presence of a p38MAPK inhibitor. Considering the entirety of these data comparing various IgG isotypes and subsequent effector function by assaying neuroprotection and microglial activation, we propose that full effector function of an anti-A␤ antibody is not necessary for neuroprotective effects and is likely deleterious when considering enhanced microglial activation as measured by p38MAPK activity and relative TNF␣ release.
MABT (also known as crenezumab), a humanized anti-A␤ IgG4 effector-reduced antibody, was selected for its in vitro and in vivo efficacy, including ability to protect neurons from A␤ oligomer-induced toxicity. MABT was also selected for its ability to promote microglial engulfment of A␤ without aberrantly activating microglia. Based on these preclinical data, we hypothesize that MABT would have a reduced risk of vascular-related findings, which are likely a consequence of an anti-A␤ antibody binding aggregated A␤ and maintaining full effector function to elicit a proinflammatory reaction around vascular amyloid. Supported by these preclinical data, a single and multiple dose, multicenter, randomized, placebo-controlled, double-blind phase I study to assess safety, pharmacokinetics, and pharmacodynamics was conducted in patients with mild-to-moderate AD. Magnetic resonance imaging results from this study are consistent with the hypothesis proposed herein, as no patients showed signs of vasogenic edema after either single or multiple doses. Moving forward, larger clinical studies are underway to fully test the efficacy and safety of crenezumab in AD patients.
